Muutke küpsiste eelistusi

E-raamat: Oxford Desk Reference: Oncology

Edited by , Edited by (Consultant Clinical Oncologist, Cambridge University Hospitals NHS Foundation Trust, UK), Edited by (Consultant in TYA and Medical Oncology, Cambridge University Hospitals NHS Founda), Edited by (Professor Emeritus, University of East Anglia, Norfolk, UK)
  • Formaat: 672 pages
  • Sari: Oxford Desk Reference Series
  • Ilmumisaeg: 01-Apr-2021
  • Kirjastus: Oxford University Press
  • Keel: eng
  • ISBN-13: 9780191062605
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 79,16 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: 672 pages
  • Sari: Oxford Desk Reference Series
  • Ilmumisaeg: 01-Apr-2021
  • Kirjastus: Oxford University Press
  • Keel: eng
  • ISBN-13: 9780191062605
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

This easy-to-read, practical guide distils and compiles all the disparate literature on cancer into one succinct volume. It includes the essential, evidence-based clinical guidelines needed for the safe and effective management of patients with cancer, and has a clear layout to allow for quick
reference whilst on the ward.

All aspects of cancer and its management are covered, including prevention, screening, diagnosis, and treatment. The text begins by outlining the clinical approach to suspected cancer and the principles of multidisciplinary prevention and management. It then progresses through site-specific cancer
management, including head and neck, CNS, thoracic, breast, gastrointestinal system, genitourinary system, female genital system, skin, musculoskeletal system, haemopoietic system, and endocrine. Later chapters cover oncological emergencies and acute oncology, and special situations such as cancer
in younger and older people, and pregnancy and fertility.

The guide also offers information about coping with the lifestyle and social issues that may arise with a diagnosis of cancer, such as insurance, travel and support, and includes a chapter dedicated to palliative care for the cancer patient. A unique appendix of clinical management flowcharts
assists fast, appropriate decision-making.

Arvustused

This easy-to-read, practical guide distils and compiles all the disparate literature on cancer into one succinct volume. It includes the essential, evidence-based clinical guidelines needed for the safe and effective management of patients with cancer, and has a clear layout to allow for quick reference whilst on the ward. * ANTICANCER RESEARCH *

List of abbreviations
xix
Contributors xxix
1 Clinical Approach To Suspected Cancer
1(7)
1.1 Overview
2(1)
1.2 Lung cancer
2(1)
1.3 Mesothelioma
2(1)
1.4 Breast cancer
2(1)
1.5 Urological cancer
3(1)
1.6 Nervous system tumours
3(1)
1.7 Upper gastrointestinal cancer
4(1)
1.8 Lower gastrointestinal cancer
4(1)
1.9 Gynaecological cancer
5(1)
1.10 Haematological cancer
5(1)
1.11 Head and neck cancer
6(1)
1.12 Thyroid cancer
6(1)
1.13 Bone cancer and sarcoma
6(1)
1.14 Skin cancer---melanoma
7(1)
1.15 Skin cancer---non-melanoma
7(1)
1.16 Further reading and internet resources
7(1)
2 Concepts Of Multidisciplinary Management
8(40)
2.1 Cancer prevention
9(2)
2.2 Cancer screening
11(1)
2.3 Cancer genetics
12(5)
2.4 Genetic counselling
17(5)
2.5 Principles of cancer diagnosis and management
22(5)
2.6 Principles of surgical oncology
27(2)
2.7 Radiotherapy
29(4)
2.8 Systemic therapy
33(9)
2.9 Clinical trials
42(6)
3 Tumours Of The Head And Neck
48(22)
3.1 Principles of management for cancer of the head and neck
49(5)
3.2 Tumours of the eye, orbit, and ear
54(2)
3.3 Salivary gland cancers
56(2)
3.4 Nose, nasal cavity, and paranasal sinuses
58(1)
3.5 Nasopharynx
59(2)
3.6 Lip and oral cavity
61(1)
3.7 Oropharynx
62(1)
3.8 Hypopharynx
63(1)
3.9 Larynx
64(2)
3.10 Uncommon tumours of the head and neck
66(1)
3.11 Management of neck nodes
67(3)
4 Tumours Of The Central Nervous System
70(26)
4.1 Primary brain tumours
71(1)
4.2 Clinicopathology of brain tumours
72(2)
4.3 Presentation and general management of primary brain tumours
74(2)
4.4 Surgical management of primary brain tumours
76(2)
4.5 Radiotherapy for primary brain tumours
78(2)
4.6 Chemotherapy and new agents for primary brain tumours
80(1)
4.7 Outcome and management of recurrence in primary brain tumours
81(3)
4.8 Summary of management for primary brain tumours
84(1)
4.9 Brain metastases overview
85(2)
4.10 Treatment options for brain metastases
87(2)
4.11 Outcome and summary for brain metastases
89(1)
4.12 Spinal cord tumours overview
90(2)
4.13 Management of spinal cord tumours
92(1)
4.14 Outcome in spinal tumours
93(1)
4.15 Further reading and internet resources
94(2)
5 Thoracic Tumours
96(21)
5.1 Primary tracheal tumours
97(1)
5.2 Lung cancer overview
97(1)
5.3 Diagnosis and staging of lung cancer
98(2)
5.4 Pathology of lung cancer
100(3)
5.5 Treatment of stage I and II non-small cell lung cancer
103(1)
5.6 Treatment of stage III non-small cell lung cancer
104(2)
5.7 Treatment of stage IV non-small cell lung cancer
106(3)
5.8 Small cell lung cancer
109(2)
5.9 Bronchial carcinoid
111(1)
5.10 Large cell neuroendocrine carcinoma
112(1)
5.11 Malignant pleural mesothelioma
112(2)
5.12 Thymic tumours
114(3)
6 Breast Cancer
117(23)
6.1 Breast cancer overview
118(1)
6.2 Clinical presentation, diagnosis, and staging of breast cancer
119(6)
6.3 Management of breast cancer: Carcinoma in situ
125(1)
6.4 Loco-regional treatment of invasive breast cancer: Surgery
126(1)
6.5 Loco-regional treatment of invasive breast cancer: Radiation therapy
127(1)
6.6 Systemic treatment for early breast cancer
128(4)
6.7 Management of locally advanced breast cancer
132(1)
6.8 Management of recurrent and metastatic breast cancer (MBC)
133(4)
6.9 Male breast cancer
137(1)
6.10 BRCA and hereditary breast cancer
138(2)
7 Cancers Of The Gastrointestinal System
140(56)
7.1 Epidemiology of oesophageal cancer
141(2)
7.2 Treatment of localized disease for oesophageal cancer
143(2)
7.3 Treatment of advanced disease for oesophageal cancer
145(1)
7.4 Epidemiology of gastric cancer
145(3)
7.5 Treatment of localized disease for gastric cancer
148(1)
7.6 Treatment of advanced disease for gastric cancer
149(2)
7.7 Hepatocellular cancer
151(7)
7.8 Biliary tract tumours overview
158(7)
7.9 Pancreatic cancer overview
165(3)
7.10 Treatment of resectable pancreatic cancer
168(2)
7.11 Treatment of unresectable and metastatic pancreatic cancer
170(1)
7.12 Uncommon pancreatic tumours
171(1)
7.13 Tumours of the small intestine
172(2)
7.14 Colorectal cancer overview
174(2)
7.15 Clinical features, diagnosis, and staging of colorectal cancer
176(3)
7.16 Colorectal cancer: Localized disease
179(2)
7.17 Adjuvant treatment for colorectal cancer
181(4)
7.18 Treatment of advanced colorectal cancer
185(4)
7.19 Prognosis, follow-up, and management of recurrence of colorectal cancer
189(2)
7.20 Anal cancer
191(5)
8 Cancers Of The Genitourinary System
196(38)
8.1 Cancer of the kidney
197(3)
8.2 Non-surgical management of cancer of the kidney
200(2)
8.3 Urothelial and bladder cancer overview
202(2)
8.4 Management of localized and muscle invasive disease of bladder cancer
204(2)
8.5 Management of advanced and metastatic disease of bladder cancer
206(2)
8.6 Management of non-transitional urothelial cancer
208(1)
8.7 Cancer of the ureter and renal pelvis
209(1)
8.8 Prostate cancer overview
210(1)
8.9 Clinical features, diagnosis, staging, natural history, screening, and prognosis of prostate cancer
211(3)
8.10 Treatment of localized disease for prostate cancer
214(3)
8.11 Treatment of advanced disease for prostate cancer
217(1)
8.12 Detection and treatment of recurrence of prostate cancer
218(2)
8.13 Palliative care and symptom control for prostate cancer
220(1)
8.14 Testicular cancer overview
221(2)
8.15 Clinical features, diagnosis, TIN, staging, and prognosis for testicular cancer
223(2)
8.16 Management of low stage seminoma testicular cancer
225(2)
8.17 Management of low stage non-seminoma testicular cancer
227(1)
8.18 Prognosis and management of advanced testicular cancer disease
228(2)
8.19 Testicular cancer follow-up
230(1)
8.20 Penile cancer overview
231(1)
8.21 Management of penile cancer
232(2)
9 Cancers Of The Female Genital System
234(53)
9.1 Cervical cancer overview
235(1)
9.2 Clinical features, investigations, staging, and prognosis of cervical cancer
236(2)
9.3 Management of cervical cancer
238(3)
9.4 Recurrent cervical cancer
241(1)
9.5 Role of chemotherapy
241(1)
9.6 Treatment-related morbidity for cervical cancer
242(1)
9.7 Newer approaches to cervical cancer
242(1)
9.8 Endometrial cancer
243(3)
9.9 Management of endometrial cancer
246(1)
9.10 Role of radiotherapy
247(2)
9.11 Role of chemotherapy and hormonal agents
249(1)
9.12 Recurrence and metastasis
250(1)
9.13 Uterine sarcomas
251(4)
9.14 Epithelial ovarian cancer
255(2)
9.15 Investigations, staging, and prognosis for epithelial ovarian cancer
257(1)
9.16 Early stage disease of epithelial ovarian cancer
258(1)
9.17 Advanced stage disease of epithelial ovarian cancer
259(2)
9.18 Epithelial ovarian cancer: Recurrent disease
261(2)
9.19 Epithelial ovarian cancer: Palliative care issues and conclusion
263(1)
9.20 Malignant ovarian germ cell tumours
264(2)
9.21 Management of malignant ovarian germ cell tumours
266(2)
9.22 Prognosis, surveillance, and management of recurrence in malignant ovarian germ cell tumours
268(1)
9.23 Sex cord-stromal tumours
269(3)
9.24 Borderline ovarian tumours
272(1)
9.25 Uncommon ovarian tumours
273(1)
9.26 Gestational trophoblastic disease overview
273(5)
9.27 Special situations
278(3)
9.28 Cancers of the vulva and vagina
281(6)
10 Cancers Of The Skin
287(21)
10.1 Introduction, clinical features, and staging of cutaneous melanoma
288(1)
10.2 Management of loco-regional disease for cutaneous melanoma
289(2)
10.3 Management of metastatic disease for cutaneous melanoma
291(4)
10.4 Non-cutaneous melanoma
295(1)
10.5 Basal cell carcinoma
296(4)
10.6 Squamous cell carcinoma
300(2)
10.7 Merkel cell carcinoma
302(1)
10.8 Kanosi's sarrnrm
303(2)
10.9 Malignant skin adnexal tumours
305(1)
10.10 Skin cancer in organ transplant recipients
306(2)
11 Cancers Of The Musculoskeletal System
308(21)
11.1 Bone tumours overview
309(3)
11.2 Osteosarcoma
312(2)
11.3 Ewing's sarcoma
314(3)
11.4 Rare bone tumours
317(2)
11.5 Soft tissue sarcomas overview
319(2)
11.6 Management of localized soft tissue sarcoma
321(2)
11.7 Management of locally advanced and metastatic disease for soft tissue sarcomas
323(2)
11.8 Retroperitoneal sarcoma
325(1)
11.9 Gastrointestinal stromal tumour
326(2)
11.10 Future directions in soft tissue sarcoma
328(1)
12 Tumours Of The Haemopoietic System
329(64)
12.1 Hodgkin lymphoma
330(2)
12.2 Clinical features, diagnosis, and staging for Hodgkin lymphoma
332(1)
12.3 Treatment of early stage Hodgkin lymphoma
333(2)
12.4 Treatment of advanced stage Hodgkin lymphoma
335(1)
12.5 Management of relapsed Hodgkin lymphoma
336(2)
12.6 Long-term toxicities and fertility issues of Hodgkin lymphoma
338(1)
12.7 Non-Hodgkin lymphoma
339(2)
12.8 Clinical features of non-Hodgkin lymphoma
341(2)
12.9 Treatment of low-grade disease
343(1)
12.10 Diffuse large B-cell lymphoma
344(1)
12.11 Mantle cell lymphoma
345(1)
12.12 Cutaneous non-Hodgkin lymphomas
346(1)
12.13 Extranodal involvement of non-Hodgkin lymphoma
347(2)
12.14 Adult acute lymphoblastic leukaemia
349(3)
12.15 Adult acute myeloid leukaemia
352(5)
12.16 Chronic myeloid leukaemia
357(5)
12.17 Chronic lymphocytic leukaemia
362(2)
12.18 Treatment for chronic lymphocytic leukaemia
364(2)
12.19 Hairy cell leukaemia
366(2)
12.20 Myelodysplasia syndrome overview
368(2)
12.21 Clinical features, staging, and prognosis of myelodysplastic syndrome
370(1)
12.22 Treatment for myelodysplastic syndrome
370(4)
12.23 Multiple myeloma
374(3)
12.24 Staging, prognosis, and treatment response criteria for multiple myeloma
377(1)
12.25 Treatment for multiple myeloma
378(6)
12.26 Solitary plasmacytoma
384(1)
12.27 Monoclonal gammopathy of undetermined significance
385(1)
12.28 Smouldering myeloma
386(1)
12.29 Waldenstrom's macroglobulinemia
387(1)
12.30 Amyloidosis
388(1)
12.31 POEMS syndrome
389(1)
12.32 Heavy chain disease
390(1)
12.33 Histiocyte disorders
391(2)
13 Endocrine Tumours
393(17)
13.1 Thyroid cancer overview
394(2)
13.2 Treatment of differentiated thyroid cancer
396(3)
13.3 Treatment of medullary carcinoma thyroid
399(2)
13.4 Treatment of anaplastic carcinoma thyroid
401(1)
13.5 Primary thyroid lymphoma
402(1)
13.6 Parathyroid cancer
403(1)
13.7 Adrenocortical carcinoma
404(2)
13.8 Neuroendocrine tumours
406(4)
14 Paediatric Tumours
410(15)
14.1 Leukaemia
411(2)
14.2 Lymphoma
413(3)
14.3 Paediatric central nervous system tumours
416(5)
14.4 Paediatric solid tumours and kidney tumours
421(1)
14.5 Sarcomas
422(1)
14.6 Neuroblastoma
423(1)
14.7 Other paediatric tumours and Langerhans cell histiocytosis
424(1)
14.8 Internet resources
424(1)
15 Oncological Emergencies And Acute Oncology
425(25)
15.1 Oncological emergencies and acute oncology
426(1)
15.2 Tumour lysis syndrome
426(1)
15.3 Hypercalcaemia
427(1)
15.4 Hyponatraemia
428(1)
15.5 Hyperkalaemia
429(1)
15.6 Hypoglycaemia
430(1)
15.7 Hyperuricaemia
430(1)
15.8 Febrile neutropenia
431(2)
15.9 Catheter associated infections
433(1)
15.10 Nausea, vomiting, and diarrhoea
433(1)
15.11 Vascular complications
434(2)
15.12 Stridor and airway obstruction
436(1)
15.13 Superior vena cava obstruction
437(1)
15.14 Gastrointestinal obstruction
438(1)
15.15 Urinary tract obstruction
438(1)
15.16 Thrombocytopenia and disseminated intravascular coagulation
439(1)
15.17 Gastrointestinal bleeding
440(1)
15.18 Genitourinary bleeding
441(1)
15.19 Cardiorespiratory
442(1)
15.20 Cardiac tamponade
442(1)
15.21 Pleural effusion
443(1)
15.22 Brain metastases and raised intracranial pressure
444(1)
15.23 Spinal cord compression
444(1)
15.24 Impending and pathological fractures
445(1)
15.25 Immunotherapy-related emergencies
446(4)
16 Special Situations In Oncology
450(32)
16.1 Teenage and young adult malignancies
451(2)
16.2 Cancer in older people
453(3)
16.3 Cancer in pregnant women
456(3)
16.4 Cancer of unknown primary site
459(2)
16.5 Fertility and cancer
461(1)
16.6 Late effects
462(3)
16.7 Cancer survivorship
465(1)
16.8 Travel
466(2)
16.9 Insurance
468(1)
16.10 Vaccination
469(3)
16.11 Lifestyle choices after cancer
472(3)
16.12 Complementary therapies
475(2)
16.13 Supportive care during chemotherapy
477(5)
17 Palliative Care
482(31)
17.1 Pain management
483(7)
17.2 Nausea and vomiting
490(3)
17.3 Malignant bowel obstruction
493(2)
17.4 Constipation
495(1)
17.5 Diarrhoea
496(1)
17.6 Hiccups
497(1)
17.7 Depression
498(1)
17.8 Delirium
499(2)
17.9 Oral care
501(1)
17.10 Cancer-related fatigue
502(1)
17.11 Cancer cachexia
503(1)
17.12 Breathlessness
504(1)
17.13 Cough
505(1)
17.14 Haemoptysis
506(1)
17.15 Symptom clusters
507(1)
17.16 End of life care
508(5)
18 Clinical Management Of Cancers---Flowcharts
513(18)
Appendix 1 Systemic therapy regimens 531(6)
Appendix 2 Radiotherapy fractionation 537(8)
Appendix 3 Glomerular filtration rate 545(2)
Index 547
Dr Ajithkumar is a Consultant Clinical Oncologist at Addenbrooke's Hospital. He undertook a research fellowship in the Royal Marsden Hospital, London followed by speciality training in Clinical Oncology in the Eastern Deanery before becoming a Consultant Clinical Oncologist at the Bristol Haematology and Oncology Centre in 2006. In 2009 he moved to Norfolk and Norwich University Hospitals, subsequently moving to Cambridge in 2014. His research interest is to optimize the combination of radiotherapy with novel agents in paediatric brain tumours and hepato-pancreatico-biliary tumours to improve clinical outcomes. Dr Ajithkumar is Chair of the European Society of Paediatric Oncology (SIOPE) Brain Tumour Radiotherapy group. He is the principal investigator for the international Pediatric Normal Tissue Effects in the Clinic (PENTEC) Re-irradiation working group. He is also the radiotherapy lead for the CCLG CNS GCT subgroup and the radiotherapy research lead for the Cancer Research Network: Eastern.

Ann Barrett is Emeritus Professor of Oncology at the University of East Anglia, England, and was formerly deputy dean of the School of Medicine and lead clinician for oncology at the Norfolk and Norwich University Hospital NHS Trust. She was awarded an OBE in 2010 for services to medicine and is a fellow of the Royal College of Surgeons in Ireland.

Dr Hatcher is the Clinical and Regional lead for sarcoma and for teenagers and young adults with a variety of types of cancer. She specialises in sarcomas, paediatric tumours, late effects and survivorship and other rare cancers. She qualified in medicine at the University of Cambridge and has trained at the Royal Marsden Hospital in London. Her PhD and post-doctoral research investigated the genetics of tumour progression and secondary cancers. She has worked at the National Cancer Institute in the USA and the Haemonc unit at the Hospital of the University of Pennsylvania. Her current research interests include drug treatments in sarcomas, and psychological impacts of cancer. She is a member of the NCRN sarcoma clinical studies group, Regional Lead for sarcoma research and lead investigator in several multicentre and international trials.

Dr Sarah Jefferies is the Clinical Director for Cancer at Addenbrooke's Hospital. She qualified from University College London and trained in clinical oncology at the Royal Marsden Hospital. She undertook a PhD at the Institute of Cancer Research. Dr Jefferies specialist interests are the management of central nervous system (CNS) tumours and thyroid cancers. Dr Jefferies is lead investigator for a number of multicentre studies for CNS and thyroid tumours. She has an interest in teaching and leads both national and international courses in the management of CNS tumours. She is a member of the National Cancer Research Institute Brain Tumour group and is the chair of the Glioma Sub-group.